Association of Circulating CD103+ T Cells with Major Pathological Response in a Randomized Phase 2 Trial of Neoadjuvant Durvalumab with or Without Stereotactic Body Radiotherapy in Patients with Early-Stage Non-Small Cell Lung Cancer.
JOURNAL OF CLINICAL ONCOLOGY（2023）
Key words
Biomarkers for Immunotherapy,Tumor Microenvironment
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined